Analysis Regulatory

FDA clears Infilbray, first therapy for neurological symptoms of Type 3 Gaucher disease

Genzyme's venglustat tablets are approved for adults and children from 15 kg, with psychiatric risks flagged in the safety information. Much of the detail that matters to teams is not yet public.

VigiEye editorial · Thu 19 Nov 2026

What happened

On 18 November 2026 the US Food and Drug Administration approved Infilbray (venglustat) tablets, from Genzyme, a Sanofi unit. The agency describes it as the first treatment for the neurological symptoms of Type 3 Gaucher disease. The approval covers adults and children weighing at least 15 kg.

The FDA's announcement also highlights psychiatric risks in the product's safety information. The records available to us do not say how those risks are presented in the label, what monitoring is required, or whether any risk-management programme applies. We therefore do not characterise them beyond what the FDA has said.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Sources this analysis is based on

Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.

More analysis & opinionAll →